Gavin S Tan1, Laura Kuehlewein, Srinivas R Sadda, David Sarraf, Steven D Schwartz. 1. *Department of Ophthalmology, Jules Stein Eye Institute, UCLA School of Medicine, Los Angeles, California; †Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore; and ‡Doheny Eye Institute, David Geffen School of Medicine, UCLA, Los Angeles, California.
Abstract
PURPOSE: To report the optical coherence tomographic angiography findings and response to treatment in a case of macular telangiectasia Type 2 with subretinal neovascularization. METHODS: Case report. RESULTS: A 64-year-old man with macular telangiectasia Type 2 developed subretinal neovascularization, which was imaged on optical coherence tomographic angiography. He was treated with intravitreal aflibercept, and there was a remarkable reduction of flow in the subretinal neovascular network on optical coherence tomographic angiography. CONCLUSION: Optical coherence tomographic angiography provides detailed information on the retinal microvasculature and subretinal neovascularization in macular telangiectasia Type 2. It can be used to assess response to treatment.
PURPOSE: To report the optical coherence tomographic angiography findings and response to treatment in a case of macular telangiectasia Type 2 with subretinal neovascularization. METHODS: Case report. RESULTS: A 64-year-old man with macular telangiectasia Type 2 developed subretinal neovascularization, which was imaged on optical coherence tomographic angiography. He was treated with intravitreal aflibercept, and there was a remarkable reduction of flow in the subretinal neovascular network on optical coherence tomographic angiography. CONCLUSION: Optical coherence tomographic angiography provides detailed information on the retinal microvasculature and subretinal neovascularization in macular telangiectasia Type 2. It can be used to assess response to treatment.
Authors: Anne P Runkle; Peter K Kaiser; Sunil K Srivastava; Andrew P Schachat; Jamie L Reese; Justis P Ehlers Journal: Invest Ophthalmol Vis Sci Date: 2017-07-01 Impact factor: 4.799